Price Alert

Alto Ingredients Inc. (ALTO)

NASDAQ: ALTO · Real-Time Price · USD

1.06

-0.01 (-0.93%)

At close: Sep 26, 2025, 10:58 AM

-0.93% (1D)

Bid	1.06
Market Cap	82.43M
Revenue (ttm)	933.14M
Net Income (ttm)	-66.83M
EPS (ttm)	-0.92
PE Ratio (ttm)	-1.16
Forward PE	-21.4
Analyst	Buy
Dividends	n/a

Ask	1.08
Volume	29,745
Avg. Volume (20D)	273,028
Open	1.06
Previous Close	1.07
Day's Range	1.06 - 1.08
52-Week Range	0.76 - 2.05
Beta	0.32
Ex-Dividend Date	n/a

About ALTO

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol ALTO

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for ALTO stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

Alto Ingredients Inc. is scheduled to release its earnings on Nov 5, 2025, after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 month ago

+0%

Alto Ingredients shares are trading lower after th... Unlock content with Pro Subscription

10 months ago

-37.63%

Alto Ingredients shares are trading lower after the company reported worse-than-expected Q3 financial results.

News

1 month ago · businesswire.com

Victoria's Secret Has Opened Its New Flagship Store in Miami Beach, Marking a Bold New Chapter for the Iconic Brand

MIAMI--(BUSINESS WIRE)--ALTO Real Estate Funds announced the opening of Victoria's Secret's flagship store. After relocating from a nearby site, Victoria's Secret secured a 12-year lease with ALTO Rea...

1 month ago · seekingalpha.com

Alto Ingredients, Inc. (ALTO) Q2 2025 Earnings Call Transcript

Alto Ingredients, Inc. (NASDAQ:ALTO ) Q2 2025 Earnings Conference Call August 6, 2025 5:00 PM ET Company Participants Bryon T. McGregor - CEO, President & Director Robert R.

1 month ago · zacks.com

Alto Ingredients (ALTO) Reports Q2 Loss, Beats Revenue Estimates

Alto Ingredients (ALTO) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to a loss of $0.05 per share a year ago.

3 months ago · businesswire.com

Alto Neuroscience Identifies Biomarker and Reports Positive Pharmacodynamic Results from Exploratory Phase 2 Proof-of-Concept Trial of ALTO-203

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $ANRO #PrecisionPsychiatry--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel prec...